SpringerProtocols: Abstract: Factor Xa Inhibitors

Factor Xa Inhibitors

By: Jeanine M. Walenga², Walter P. Jeske², Debra Hoppensteadt³, Jawed Fareed³

Abstract

Full Text

Download PDF (173K)

Serine proteases play an important role in the process of thrombogenesis. In the coagulation network, various serine proteases are activated that facilitate the formation of factor Xa (1). The serine protease factor Xa has a central role in coagulation and platelet activation. Factor Xa is an essential component of the prothrombinase complex, and leads to the formation of thrombin. Thus, the inhibition of factor Xa represents an important strategy in the development of new antithrombotic drugs.

Affiliation(s): (2) Departments of Thoracic-Cardiovascular Surgery and Pathology, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL
(3) Department of Pathology, Loyola University Medical Center, Maywood, IL

Book Title: Anticoagulants, Antiplatelets, and Thrombolytics

Series: Methods in Molecular Medicine | Volume: 93 | Pub. Date: Nov-03-2003 | Page Range: 95-117 | DOI: 10.1385/1-59259-658-4:95

Subject: Molecular Medicine

References

Download References

1.	Samama, M. M., Walenga, J. M., Kaiser, B., and Fareed, J. (1997) Specific factor Xa inhibitors, in Cardiovascular Thrombosis: Thrombocardiology (Verstraete, M., Fuster, V., and Topol, E., eds.), Lippincott-Raven, Brussels, Belgium, pp. 173–188.

2.	Weitz, J. I. and Hirsh, J. (1998) New antithrombotic agents. Chest 114, 715S–727S.

3.	Stürzebecher, J., Stürzebecher, U., Vieweg, H., Wagner, G., Hauptmann, J., and Markwardt, F (1989) Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency. Thromb. Res. 54, 245–252.

4.	Hauptmann, J., Kaiser, B., Nowak, G., Stürzebecher, J., and Markwardt, F (1990) Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb. Haemostasis 63, 220–223.

5.	The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. 335(11), 775–782.

6.	Antman, E. M., for the TIMI 9B Investigators (1996) Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 94, 911–921.

7.	Kaiser, B. and Hauptmann, J. (1994) Factor Xa inhibitors as novel antithrombotic agents: facts and perspectives. Cardiovas. Drug Rev. 12(3), 225–236.

8.	Kaiser, B. (1997) Factor Xa versus factor IIa inhibitors. Clin. Appl. Thrombosis/Hemostasis 3(1), 16–24.

9.	Meddahi, S., Bara, L., Uzan, A., and Samama, M. M. (1996) Pharmacologic modulation of human clots associated thrombin and prothrombinase activities by a direct anti Xa drug, r-hirudin and low molecular weight heparin. Haemostasis 26(Suppl. 3), 578.

10.	Hoppensteadt, D. (1996) Doctoral thesis: Tissue factor pathway inhibitor as a modulator of post-surgical thrombogenesis. Experimental and clinical studies. University of London, London, UK, October 1996.

11.	Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., and Hirsh, J. (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. j. Clin. Investig. 86, 385–391.

12.	Eisenberg, P. R., Siegel, J. E., Abendschein, D. R., and Miletich, J. P. (1993) Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Investig. 91, 1877–1883.

13.	Prager, N. A., Abendschein, D. R., McKenzie, C. R., and Eisenberg, P. R. (1995) Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92, 962–967.

14.	McKenzie, C. R., Abendschein, D. R., and Eisenberg, P. R. (1996) Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler. Thromb. Vase. Biol. 16, 1285–1291.

15.	Schwartz, R. S., Holmes, D. R., Jr., and Topol, E. J. (1992) The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20, 1284–1293.

16.	Kanthou, C. and Benzakour, O. (1995) Cellular effects of thrombin and their signaling pathways. Cell Pharmacol. 2, 293–302.

17.	Benzakour, O. and Kanthou, C. (1996) Cellular and molecular events in athero-genesis: Basis for pharmacological and gene therapy approaches to restenosis. Cell Pharmacol. 3, 7–22.

18.	McNamara, C. A., Sarembock, I. J., Bachhuber, B. G., et al. (1996) Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin. Thromb. Hemost. 22, 139–144.

19.	Ko, F. N., Yang, Y. C, Huang, S. C, and Ou, J. T (1996) Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J. Clin. Investig. 98, 1493–1501.

20.	Gasic, G. P., Arenas, C. P., Gasic, T B., and Gasic, G J. (1992) Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA 89, 2317–2320.

21.	Ragosta, M., Gimple, L. W., Gertz, D., et al. (1994) Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 89, 1262–1271.

22.	Schwartz, R. S., Holder, D. J., Holmes, D. R., Jr., Veinot, J. P., Camrud, A. R., Jorgenson, M. A., et al. (1996) Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor. Results in a porcine model. Circulation 93, 1542–1548.

23.	Tuszynski, G. P., Gasic, T B., and Gasic, G. J. (1987) Isolation and characterization of antistasin. J. Biol. Chem. 262, 9718–9723.

24.	Dunwiddie, C. T, Thornberry, N. A., Bull, H. G., et al. (1989) Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem. 264(28), 16,694–16,699.

25.	Rigbi, M., Jackson, C. M., Atamna, H., et al. (1995) FXa inhibitor from the saliva of the leech Hirudo medicinalis. Thromb. Haemostasis 73, 1306.

26.	Jordan, S. P., Mao, S. S., Lewis, S. D., and Shafer, J. A. (1992) Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. Biochemistry 31, 5374–5380.

27.	Jordan, S. P., Waxman, L., Smith, D. E., and Vlasuk, G P. (1990) Tick anticoagulant peptide: Kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 29, 11,095–11,100.

28.	Krishnaswamy, S., Vlasuk, G. P., and Bergum, P. W. (1994) Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 33, 7897–7907.

29.	Vlasuk, G. P. (1993) Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa. Thromb. Haemostasis 70, 212–216.

30.	Vlasuk, G. P., Ramjit, D., Fujita, T., et al. (1991) Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemostasis 65, 257–262.

31.	Fioravanti, C, Burkholder, D., Francis, B., Siegl, P. K. S., and Gibson, R. E. (1993) Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb. Res. 71, 317–324.

32.	Wong, P. C, Crain, E. J., Jr., Nguan, O., Watson, C. A., and Racanelli, A. (1996) Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb. Res. 83(2), 117–126.

33.	Lynch, J. J., Sitko, G R., Lehman, E. D., and Vlasuk, G P. (1995) Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb. Haemostasis 74, 640–645.

34.	Schaffer, L. W., Davidson, J. T, Vlasuk, G. P., and Siegl, P. K. S. (1991) Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 84, 1741–1748.

35.	Ørvim, U., Barstad, R. M., Vlasuk, G. P., and Sakariassen, K. S. (1995) Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler. Thromb. Vase. Biol. 15, 2188–2194.

36.	Mellott, M. J., Stranieri, M. T, Sitko, G R., Stabilito, I. I., Lynch, J. J., and Vlasuk, G P. (1993) Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombolysis. Fibrinolysis 7, 195–202.

37.	Sitko, G R., Ramjit, D. R., Stabilito, I. I., Lehmann, D., Lynch, J. J., and Vlasuk, G. P. (1992) Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 85, 805–815.

38.	Lifkovits, J., Malycky, J. L., Rao, J. S., Hart, C. E., Plow, E. F, Topol, E. J., et al. (1996) Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. 28, 1858–1865.

39.	Vlasuk, G. P., Bergum, P. W., Brunck, T. K., et al. (1995) Anticoagulant repertoire of hematophagous nematodes. Thromb. Haemostasis 73, 1305.

40.	Broze, G. J., Jr. (1995) Tissue factor pathway inhibitor. Thromb. Haemostasis 74, 90–93.

41.	Jort, P. F H. (1957) Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scan. J. Lab. Investig. 9(Suppl. 27), 81–183.

42.	Kaiser, B., Jeske, W., Hoppensteadt, D., Walenga, J. M., and Fareed, J. (1996) Anticoagulant and antithrombotic effects of the synthetic heparin pentasaccharide and the direct factor Xa inhibitor DX-9065a after i.v. administration in rabbits. Blood 88(Suppl. 1), 67b.

43.	Wang, Z., Hebert, D., Kaplan, A. V., Creasy, A., and Galluppi, G. R. (1996) Persistent inhibition to 12 hours of mural platelet thrombosis after a single local infusion of tissue factor pathway inhibitor at the site of angioplasty. Circulation 94(8), I–268.

44.	Kaiser, B., Hoppensteadt, D., and Fareed, J. (2000) Tissue factor pathway inhibitor for cardiovascular disorders. Emerging Drugs 5(1), 1–15.

45.	Fareed, J., Callas, D., Hoppensteadt, D., and Walenga, J. (1995) Modulation of endothelium by heparin and related polyelectrolytes, in The Endothelial Cell in Health and Disease (Vane, J. R., Born, G. V. R., and Welzel, D., eds.), FK Schattauer Verlagsgesellschaft mbH, Stuttgart, Germany, pp. 165–182.

46.	Herbert, J. M., Bernat, A., Dol, F, Hérault, J. P., Crepon, B., and Lormeau, J. C. (1996) DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 276, 1030–1038.

47.	Nagahara, T., Katakura, S., Yokoyama, Y., et al. (1995) Design, synthesis and biological activities of orally active coagulation factor Xa inhibitors. Eur. J. Med. Chem. 30(Suppl.), 140s–143s.

48.	Hara, T., Yokoyama, A., Ishihara, H., Yokoyama, Y, Nagahara, T., and Iwamoto, M. (1994) DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemostasis 1, 314–319.

49.	Katakura, S., Nagahara, T., Hara, T., and Iwamoto, M. (1993) A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. Biochem. Biophys. Res. Commun. 197, 965–972.

50.	Katakura, S., Nagahara, T., Hara, T., Kunitada, S., and Iwamoto, M. (1995) Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases. Eur. J. Med. Chem. 30, 387–394.

51.	Fareed, D., Wyma, D., Ahmad, S., Iqbal, O., and Kunitada, S. (1997) Anticoagulant and antithrombotic effects of a synthetic factor Xa inhibitor (DX-9065a) [Abstract]. Thromb. Haemostasis Supp. 292.

52.	Emaciate, T., Tsuji, T., Matsuoka, A., Giddings, J. C, and Yamamoto, J. (1997) The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric vessels. Thromb. Res. 85, 45–51.

53.	Yokoyama, T, Kelly, A. B., Marzec, U. M., Hanson, S. R., Kunitada, S., and Harker, L. A. (1995) Antithrombotic effects of orally active synthetic antagonists of activated factor X in nonhuman primates. Circulation 92, 485–491.

54.	Hara, T, Yokoyama, A., Tanabe, K., Ishihara, H., and Iwamoto, M. (1995) DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemostasis 74, 635–639.

55.	Yamazaki, M., Asakura, H., Aoshima, K., et al. (1994) Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb. Haemostasis 72, 393–396.

56.	Yamazaki, M., Asakura, H., Saito, M., Aoshima, K., Morishita, E., and Matsuda, T. (1995) Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa against experimental disseminated intravascular coagulation in rats. Thromb. Haemostasis 73, 1312.

57.	Tanabe, K., Terada, Y, Shibutani, T., Kunitada, S., and Kondo, T. (1999) A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats. Thromb. Res. 96, 135–143.

58.	Hara, T., Morishima, Y, and Kunitada, S. (1995) Selective factor Xa inhibitor, DX-9065a; suppressed hypercoagulable state during haemodialysis in cynomologus monkeys. Thromb. Haemostasis 73, 1311.

59.	Kaiser, B., Jeske, W., Walenga, J. M., and Fareed, J. (1999) Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagulation 10(8), 495–501.

60.	Hara, T., Yokoyama, A., Morishima, Y, and Kunitada, S. (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb. Res. 80, 99–104.

61.	Tanabe, K., Morishima, Y, Shibutani, T., Terada, Y, Hara, T, Shiohara, Y, et al. (1999) DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Thromb. Haemostasis 81, 828–834.

62.	Kaiser, B., Paintz, M., Scholz, O., Kunitada, S., and Fareed, J. (2000) A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats. Thromb. Res. 98(2), 175–185.

63.	Herbert, J.-M., Bono, F, Hérault, J.-P., Michaux, C, Nestor, A.-L., Guillemot, J.-C, et al. (1999) Activation of endothelial cells by factor Xa reveals a new mode of activation of the PAR-2 receptor [Abstract]. Thromb. Haemostasis (Suppl.), 693.

64.	Murayama, N., Tanaka, M., Kunitada, S., Yamada, H., Inoue, T, Terada, Y, et al. (1999) Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin. Pharmacol. Ther. 66, 258–264.

65.	Ostrem, J. A., Stringer, S., Al-Obeidi, F, et al. (1995) Characterization of an orally available and highly specific synthetic factor Xa inhibitor. Thromb. Haemostasis 73, 1306.

66.	Al-Obeidi, F. and Ostrem, J. A. (1999) Factor Xa inhibitors. Exp. Opin. Ther. Patents 9(7), 931–953.

67.	Kawasaki, T., Sato, K., Hirayama, F, et al. (1998) Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with various antithrombotic agents in a rat model of arterial thrombosis. Thromb. Haemostasis 79(4), 859–864.

68.	Ewing, W. R., Pauls, H. W., and Spada, A. P. (1999) Progress in the design of inhibitors of coagulation factor Xa. Drugs of Future 24(7), 771–787.

69.	Baum, P., Light, D., Verhallen, P., Sullivan, M., Eisenberg, P., and Abendschein, D. (1998) Antithrombotic effects of a novel antagonist of factor Xa. Circulation 98(17)(Suppl.), I79.

70.	Walenga, J. M., Jeske, W. P., Bara, L., Samama, M. M., and Fareed, J. (1997) State-of-the-art article. Biochemical and pharmacologic rationale for the development of a heparin pentasaccharide. Thromb. Res. 86(1), 1–36.

71.	Choay, J., Petitou, M., Lormeau, J. C, Sinay, P., Casu, B., and Gatti, G. (1983) Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Acta 116(2), 492–499.

72.	Sinay, P., Jaquinet, J. E., Petitou, M., et al. (1984) Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr. Res. 132, C5–C9.

73.	Petitou, M., Duchaussoy, P., Lederman, I., et al. (1986) Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide 0-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-1→4)-0-(beta-D-glucopyranosyluronic acid)-(1→4)-0-(2-deoxy-2-sulfamido-3, 6-di-0-sulfo-alpha-D-glucopyranosyl)-(1→4)-0-(2-O-sulfo-alpha-L-idopyranosyluronic acid)-(1→4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr. Res. 147, 221–236.

74.	Walenga, J. M., Petitou, M., Lormeau, J. C, Samama, M., Fareed, J., and Choay, J. (1987) Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. 46, 187–198.

75.	Walenga, J. M., Bara, L., Petitou, M., Samama, M., Fareed, J., and Choay, J. (1988) The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb. Res. 51, 23–33.

76.	Hobbelen, P. M. J., van Dinther, T. G., Vogel, G. M. T, van Boeckel, C. A. A., Moelker, H. C. T, and Meuleman, D. G. (1990) Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb. Haemostasis 63(2), 265–270.

77.	Petitou, M., and van Boeckel, C. A. A. (1992) Chemical synthesis of heparin fragments and analogues. Prog. Chem. Org. Nat. Prod. 60, 143–210.

78.	Van Boeckel, C. A. A., Beetz, T., Vos, J. N., de Jong, A. J. M., van Aelst, S. F, van den Bosch, R. H., et al. (1985) Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J. Carbohydr. Chem. 4, 293–321.

79.	Petitou, M., Lormeau, J. C, and Choay, J. (1993) A new synthetic pentasaccharide with increased anti-factor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin. Thromb. Res. 19(Suppl. 2), 143–146.

80.	Visser, A., Buiting, M. T., van Dinther, T. G., van Boeckel, C. A. A., Grootenhuis, P. G, and Meuleman, D. G (1991) The AT-III binding affinities of a series of synthetic pentasaccharide analogues. Thromb. Haemostasis 65(6), 1296.

81.	Meuleman, D. G., Hobbelen, P. M. J., van Dinther, T. G., Vogel, G. M. T., van Boeckel, C. A. A., and Moelker, H. C. T. (1991) Anti-factor Xa activity and antithrombotic activity in rats of structural analogues of the minimal antithrombin III binding sequence: Discovery of compounds with a longer duration of action than of the natural pentasaccharide. Semin. Thromb. Hemost. 17(Suppl. 1), 112–117.

82.	van Amsterdam, R. G. M., Vogel, G. M. T., Visser, A., Kop, W. J., Buiting, M. T., and Meuleman, D. G (1995) Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler. Thromb. Vase. Biol. 15(4), 495–503.

83.	Walenga, J. M., Bara, L., Hoppensteadt, D., Choay, J., Fareed, J., and Samama, M. (1991) AT III as a rate limiting factor for the measurement of pentasaccharide in laboratory assays. Thromb. Haemostasis 65(6), 1314.

84.	Lormeau, J. C, Hérault, J. P., and Herbert, J. M. (1996) Antithrombin mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to AT. Thromb. Haemostasis 76(1), 5–8.

85.	Dol, F., Gaich, C., Petitou, M., et al. (1993) The antithrombotic activity of synthetic pentasaccharides and fraxiparine is closely correlated with their respective ability to alter thromboplastin-triggered thrombin generation ex vivo. Thromb. Haemostasis 69(6), 655.

86.	Béguin, S., Choay, J., and Hemker, H. C. (1989) The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemostasis 61(3), 397–401.

87.	Lormeau, J. C. and Hérault, J. P. (1993) Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin, and a synthetic AT-III binding pentasaccharide. Thromb. Haemostasis 69(2), 152–156.

88.	Lormeau, J. C. and Hérault, J. P. (1995) The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to AT-mediated neutralization of factor Xa. Thromb. Haemostasis 74(6), 1474–1477.

89.	Walenga, J. M., Koza, M. J., Lewis, B. E., and Pifarré, R. (1996) Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thrombosis/Hemostasis 2(Suppl. 1), S21–S27.

90.	Amar, J., Caranobe, P., Sie, P., and Boneu, B. (1990) Antithrombotic potencies of heparins in relation to their anti-factor Xa and antithrombin activities: An experimental study in two models of thrombosis in the rabbit. Br. J. Haematol. 76, 94–100.

91.	Vogel, G. M. T., van Amsterdam, R. G. M., Kop, W J., and Meuleman, D. G. (1993) Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb. Haemostasis 69(1), 29–34.

92.	Weichert, W. and Breddin, H. K. (1988) Effect of low molecular weight heparins on laser-induced thrombus formation in rat mesenteric vessels. Haemostasis 18(Suppl. 3), 55–63.

93.	Hérault, J. P., Pflieger, A. M., Savi, P., et al. (1996) Comparative effects of two factor Xa inhibitors on prothrombinase assembled in different environments. Haemostasis 26, S3.

94.	Bernat, A., Hoffmann, P., Sainte-Marie, M., and Herbert, J. M. (1996) The synthetic pentasaccharide SR 90107A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits. Fibrinolysis 10(3), 151–157.

95.	Crépon, B., Donat, F., Bârzu, T., and Hérault, J. P. (1993) Pharmacokinetic (PK) parameters of AT binding pentasaccharides in three animal species: predictive value for humans. Thromb. Haemostasis 69(6), 654.

96.	Walenga, J. M. and Fareed, J. (1985) Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide. Semin. Thromb. Hemost. 11(2), 89–99.

97.	Boneu, B., Necciari, J., Cariou, R., et al. (1995) Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb. Haemostasis 74, 1468–1473.

98.	Schiele, F. J., Vuillemenot, A. R., Meneveau, N. F., et al. (1996) Initial experience of a sulphated pentasaccharide, a pure factor Xa inhibitor, in coronary angioplasty. Circulation 94(8), I–742.

99.	Elalamy, I., Lecrubier, C., Potevin, F., et al. (1995) Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb. Haemostasis 74, 1384–1385.

100.	Herbert, J. M., Heravlet, J. P., Bernat, A., Van Amsterdam, R. G., Lormeau, J. C, Petitou, M., et al. (1998) Biochemical and pharmacologic properties of SanOrg 34006, a potent and long-acting synthetic pentasaccharide. Blood 91(11), 4197–4205.

101.	Faaij, R. A., Burggraaf, J., Schoemaker, R. C, van Amsterdam, R. G. M., and Cohen, A. F (1999) A phase 1 single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers [Abstract]. Thromb. Haemostasis (Suppl.), 853.

102.	Faaij, R. A., Burggraaf, J., Schoemaker, R. C, tvan Amsterdam, R. G. M., and Cohen, A. F (1999) A phase 1 single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers. Thromb. Haemostasis (Suppl.), 490.

103.	Hérault, J. P., Bernat, A., Driguez, P. A., Duchaussoy, P., Petitou, M., and Herbert, J. M. (1999) New synthetic heparin mimetics—part 2: Biochemical and pharmacological properties. Thromb. Haemostasis (Suppl), 722.

104.	Herbert, J. M., Hérault, J. P., Bernat, A., Petitou, M. (1999) SR123781A, a synthetic heparin mimetic. Thromb. Haemostasis (Suppl.), 414.

105.	Fareed, J., Callas, D. D., Hoppensteadt, D., Jeske, W., and Walenga, J. M. (1995) Recent developments in antithrombotic agents. Exp. Opin. Invest. Drugs 4(5), 389–412.

Comments (Loading...)

Post comment/View all comments